{"title":"Cloning and expansion of antigen-specific T cells using iPS cell technology: Possible use of regenerated T cells in personalized medicine","authors":"Hiroshi Kawamoto , Kyoko Masuda , Seiji Nagano","doi":"10.1016/j.pmu.2018.05.002","DOIUrl":null,"url":null,"abstract":"<div><p><span>Recent advances in adoptive immunotherapy<span> using cytotoxic T lymphocytes (CTLs) have demonstrated that CTLs are effective in killing tumor cells </span></span><em>in vivo</em><span> for some tumor types. However, a critical issue that CTLs collected from patients are easily exhausted during expansion culture is yet to be addressed. Therefore, we have been developing a strategy that utilizes induced pluripotent stem cell<span> (iPSC) technology, based on the idea that iPSCs produced from antigen-specific CTLs would regenerate CTLs with the same antigen specificity as the original CTLs. We previously succeeded in regenerating melanoma antigen<span> MART1-specific CTLs, and more recently in producing potent CTLs expressing the CD8αβ heterodimer<span><span>. We are now developing a novel method by which non-T derived iPSCs are transduced with exogenous T cell receptor (TCR) genes. If this method is applied to the allogeneic transfusion setting wherein HLA haplotype-homozygous iPSC stocks are used as the cell source, it will be possible to prepare “off-the-shelf” </span>T cells<span>. We are also considering incorporation of a personalized medicine approach to this allogeneic setting. In such a scheme, genes encoding TCRs specific for neoantigens will be collected from patients and HLA-homo iPSCs will be transduced with these TCR genes. Using such iPSCs, it will be possible to produce allogeneic CTLs expressing autologous TCRs originating from patients.</span></span></span></span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"7 ","pages":"Pages 7-12"},"PeriodicalIF":0.0000,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2018.05.002","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized Medicine Universe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2186495018300269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Recent advances in adoptive immunotherapy using cytotoxic T lymphocytes (CTLs) have demonstrated that CTLs are effective in killing tumor cells in vivo for some tumor types. However, a critical issue that CTLs collected from patients are easily exhausted during expansion culture is yet to be addressed. Therefore, we have been developing a strategy that utilizes induced pluripotent stem cell (iPSC) technology, based on the idea that iPSCs produced from antigen-specific CTLs would regenerate CTLs with the same antigen specificity as the original CTLs. We previously succeeded in regenerating melanoma antigen MART1-specific CTLs, and more recently in producing potent CTLs expressing the CD8αβ heterodimer. We are now developing a novel method by which non-T derived iPSCs are transduced with exogenous T cell receptor (TCR) genes. If this method is applied to the allogeneic transfusion setting wherein HLA haplotype-homozygous iPSC stocks are used as the cell source, it will be possible to prepare “off-the-shelf” T cells. We are also considering incorporation of a personalized medicine approach to this allogeneic setting. In such a scheme, genes encoding TCRs specific for neoantigens will be collected from patients and HLA-homo iPSCs will be transduced with these TCR genes. Using such iPSCs, it will be possible to produce allogeneic CTLs expressing autologous TCRs originating from patients.